TARGETED THERAPY FOR
STAGE 4 CANCER
The molecular test does not just inform the treatment decision for stage 4 cancer. In many cancer types, it is the treatment decision. The drug follows from the finding.
Key Targeted Therapy Categories in Stage 4 Cancer
| Target / Class | Key Drugs | Cancer Types |
|---|---|---|
| EGFR inhibitors | Osimertinib, erlotinib, gefitinib | NSCLC (EGFR-mutated) |
| ALK/ROS1/RET inhibitors | Alectinib, lorlatinib, selpercatinib | NSCLC (ALK, ROS1, RET fusions) |
| BRAF/MEK inhibitors | Dabrafenib + trametinib, encorafenib + binimetinib | Melanoma, NSCLC, thyroid, CRC (BRAF V600E) |
| HER2-targeted agents | Trastuzumab, T-DXd, tucatinib, pertuzumab | Breast, gastric, lung, CRC (HER2+) |
| PARP inhibitors | Olaparib, niraparib, rucaparib, talazoparib | Ovarian, breast, prostate, pancreatic (BRCA/HRD) |
| CDK4/6 inhibitors | Palbociclib, ribociclib, abemaciclib | HR+/HER2- metastatic breast cancer |
| KRAS G12C inhibitors | Sotorasib, adagrasib | NSCLC, CRC, pancreatic (KRAS G12C) |
| NTRK inhibitors | Larotrectinib, entrectinib | Any cancer with NTRK fusion (tumour-agnostic) |
| FGFR inhibitors | Pemigatinib, futibatinib | Cholangiocarcinoma and other FGFR-altered cancers |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Targeted Therapy Options for Your Stage 4 Cancer?
CancerFax reviews your comprehensive molecular profile and connects you with oncologists experienced in targeted therapy for your specific mutation type.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.